'Toxgnostics': an unmet need in cancer medicine

  title={'Toxgnostics': an unmet need in cancer medicine},
  author={David N. Church and Rachel S Kerr and Enric Domingo and Dan Rosmarin and Claire Palles and Kevin F Maskell and Ian P. M. Tomlinson and David J Kerr},
  journal={Nature Reviews Cancer},
If we were to summarize the rationale that underpins medical oncology in a Latin aphorism, it might be 'veneno ergo sum'; that is, I poison, therefore I am. The burden of chemotherapy-associated toxicity is well recognized, but we have relatively few tools that increase the precision of anticancer drug prescribing. We propose a shift in emphasis from the focussed study of polymorphisms in drug metabolic pathways in small sets of patients to broader agnostic analyses to systematically correlate… 
Molecular and Functional Diagnostic Tools in Precision Oncology for Urological Malignancies
Some of the recent developments in the area of molecular diagnostics and functional testing platforms and their potential application in clinical decision making in the premises of precision oncology of urological malignancies are captured.
High-throughput pharmacogenetics identifies SLCO1A2 polymorphisms as candidates to elucidate the risk of febrile neutropenia in the breast cancer RAPP-01 trial
FN in patients receiving docetaxel in the RAPP-01 trial is significantly associated with the haplotype T–T in rs4762699 and rs2857468 in the SLCO1A2 transporter gene, which should be validated in an independent cohort.
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Clinical cancer research: the past, present and the future
Four leading cancer researchers from around the world, and who have been associated with the journal since its launch in November 2004, are asked what they have learnt over the past 10 years and how the field should progress in the next 10 years.
The Quest for Evidence for Proton Therapy: Model-Based Approach and Precision Medicine.
Pharmaceutical Applications Based on Next Generation Sequencing Technology in Oncologic Drug Development
This review aimed to provide information about the availability of next generation sequencing technology in pharmaceutical applications including areas such as tumor marker ÖZET.
“Pharmacogenetics of Cancer” - Cancer Drug Resistance special issue
© The Author(s) 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
Pharmacogenetic biomarkers for chemotherapy-induced adverse drug reactions
The use of harsh chemotherapies is motivated and accepted but, unfortunately, is often accompanied by side-effects that make it difficult to assess the effectiveness of these treatments.
Prognostic markers for colorectal cancer: estimating ploidy and stroma
  • H. Danielsen, T. Hveem, D. Kerr
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2018
A novel biomarker, combining estimates of ploidy and stroma-tumour fraction, sampled from FFPE tissue, identifies stage II CRC patients with low, intermediate or high risk of CRC disease specific death, and can reliably stratify clinically relevant patient sub-populations with differential risks of tumour recurrence and may support choice of adjuvant therapy for these individuals.


Genome-wide association study of epirubicin-induced leukopenia in Japanese patients
It is shown that genetic variants in the microcephalin 1 locus are suggestively associated with the risk of epirubicin-induced ADRs and might be applicable in development of diagnostic system for predicting therisk of the ADRs, leading to better prognosis and quality of life for patients with cancer.
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
A panel of genetic biomarkers for capecitabine monotherapy toxicity would currently comprise only the four DPYD and TYMS variants above, but the test panel might be extended to include additional, rare DPYD variants functionally equivalent to *2A and 2846A, though insufficient evidence supports its use in bolus, infusional, or combination FU.
Review: side effects of approved molecular targeted therapies in solid cancers.
The toxicity and safety of various small molecules and monoclonal antibodies used in solid tumors are reviewed, with discussion of the pathophysiology, correlation with response, and strategies for prevention and management.
5-Fluorouracil: mechanisms of action and clinical strategies
This work has shown that novel genes identified in DNA microarray profiling have the potential to identify novel genes that are involved in mediating resistance to 5-FU, and these genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to5-FU-based chemotherapy.
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
Dose reduction should be considered in patients carrying four DPYD sequence variants associated with grade 3–4 toxicity to fluoropyrimidine therapy, and a panel of clinically useful pharmacogenetic markers predicting toxicity tofluorouracil-based chemotherapy is identified.
Genetic prognostic and predictive markers in colorectal cancer
There has been an explosive increase in the number of markers thought to be associated with prognosis and treatment outcome in this disease, and this Review attempts to summarize the sometimes confusing findings, and critically assess those markers already in the public domain.
Severe 5‐fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome
This is the third patient with severe FUra toxicity secondary to an alteration in pyrimidine catabolism and the second from the authors' clinic population suggesting that the frequency of this genetic defect may be greater than previously thought.
Challenges in Interpreting the Evidence for Genetic Predictors of Ototoxicity
Analysis of two articles that purport to show an association between TPMT and COMT variants and ototoxicity as well as the related patent applications dating back to 2006 summarized statistical issues not fully addressed by the authors that appear to have confounded the results of their studies.
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
  • J. Blay, F. Chauvin, P. Biron
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
Day 5 lymphocyte counts < or = 700/microL and the type of chemotherapy regimen enable oncologists to define subgroups of patients treated with chemotherapy as those with a high intermediate, and low risk of FN.
Clinical pharmacokinetics of antitumor antifolates.
  • N. Dr
  • Biology, Medicine
  • 1999
The pharmacokinetics of the classical antifolate methotrexate have been well-defined and pharmacokinetic data can be exploited to reduce the toxicity and enhance the activity of the drug.